25 results
10-K
2024 FY
EX-19.1
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
negotiations;
major environmental incidents;
institution of, or developments in, major litigation, investigations, or regulatory actions or proceedings
8-K
EX-10.2
IXHL
Incannex Healthcare Limited
10 Sep 24
Entry into a Material Definitive Agreement
7:30am
” shall have the meaning ascribed to such term in Section 4.1(mm).
“Environmental Laws” means any federal, state, local and foreign laws relating … in the definition of Environmental Laws.
“Import Control Laws” means import control laws and regulations of any jurisdiction applicable
8-K
EX-10.1
IXHL
Incannex Healthcare Limited
10 Sep 24
Entry into a Material Definitive Agreement
7:30am
maintained against the transfer thereof.
“ELOC Warrant” has the meaning set forth in Section 13.04(f).
“Environmental Laws” shall have the meaning … is reasonably likely to cause a Material Adverse Effect.
Section 4.08 Environmental Laws. The Company and its Subsidiaries (i) have not received written
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
5 Aug 24
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
8:15am
environmental circumstances. Symptoms are variable, including feelings of persistent and excessive worry, nervousness, restlessness, difficulty concentrating
S-1/A
IXHL
Incannex Healthcare Limited
17 Jul 24
IPO registration (amended)
8:47am
to any particular environmental circumstances. Symptoms are variable, including feelings of persistent and excessive worry, nervousness, restlessness … in SEC filings, no litigation, labor or other compliance issues, environmental, intellectual property and title matters and compliance with various laws
S-1/A
EX-10.9
dm7gcv7s2c8nm49
17 Jul 24
IPO registration (amended)
8:47am
S-1
od9ux
3 Jul 24
IPO registration
6:29am
8-K
EX-99.1
woiszibstp01u0hlas
28 Feb 24
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
7:42am
6-K
EX-99.1
tx1dvn21g15tmysu 4gp
1 Sep 23
Report of Foreign Private Issuer
8:43am
6-K
EX-99.1
ylqf6keg7zwg8tae0
1 Sep 23
Report of Foreign Private Issuer
12:00am
20-F
9bysrw4m8
28 Oct 22
Annual report (foreign)
6:31am
20-F
EX-4.11
qara7jchjzm3x3l
28 Oct 22
Annual report (foreign)
6:31am
6-K
EX-99.1
x3ek55n pr9y9
19 Sep 22
Report of Foreign Private Issuer
9:38pm
6-K
EX-99.1
i4v2hft 4rxvf
9 Aug 22
Report of Foreign Private Issuer
6:01am
20FR12B/A
gg85avtz8r a0mrir
24 Feb 22
Initial registration of securities (foreign private issuers) (amended)
3:42pm
20FR12B/A
caikns79h7sron8rtw
22 Feb 22
Initial registration of securities (foreign private issuers) (amended)
6:10am
20FR12B
wtdxpm
24 Jan 22
Initial registration of securities (foreign private issuers)
8:18pm
F-1/A
dq6hxitpfgfgb
7 Dec 21
Registration statement (foreign) (amended)
5:21pm
F-1/A
wmyvb zcr2ucnbrnrw
23 Nov 21
Registration statement (foreign) (amended)
3:28pm